Charlesd Blanke News Today

The unique public-private partnership that for almost a decade has undergirded the first National Cancer Institute (NCI)-sponsored precision medicine clinical trial in lung cancer can serve as a model for future clinical research that is more rapid, innovative, and inclusive.

As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer (NSCLC), the biomarker-driven Lung Cancer Master Protocol (Lung-MAP) has enrolled higher percentages of patients who are older, patients who are from rural or socioeconomically deprived areas, and patients who have Medicaid or no insurance.

As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer (NSCLC), the biomarker-driven Lung Cancer Master Protocol (Lung-MAP) has enrolled higher percentages of patients who are older, patients who are from rural or socioeconomically deprived areas, and patients who have Medicaid or no insurance.

Vogelzang left his mark as a medical oncologist and cancer investigator, helping shepherd a handful of cancer drugs through clinical trials.

The pod, known as Sarco, was conceived as a way for people to end their lives without involving a doctor. A plan to introduce it in Switzerland has raised alarm even among right-to-die advocates.

Although younger patients tend to be more fit and receive more intensive therapy, their survival rates don’t exceed that of older patients. More

SWOG researchers to present practice-changing research at virtual ASCO 2021 "SWOG always brings an impressive portfolio of work to the ASCO annual meeting," said SWOG Chair Charles D. Blanke, MD, "and this year Im particularly excited about the research our investigators are presenting because it includes results that are likely to be practice-changing." Investigators will present 12 abstracts from SWOG-led or co-led studies and 11 abstracts from studies led by other groups within the National ...